Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
Sumitomo Dainippon Pharma and French biopharma Poxel said on April 9 that their diabetes treatment imeglimin met the primary endpoint in a Japan PIII study dubbed TIMES1 - a result that would help the partners propel their plan for the…
To read the full story
Related Article
- Sumitomo Dainippon Files Japan NDA for Poxel’s Diabetes Med
July 31, 2020
- Sumitomo/Poxel Wraps Up Japan Pivotal Program for Imeglimin with Successful Long-Term Study
December 23, 2019
- Poxel/Sumitomo’s Imeglimin Delivers Again, This Time in Insulin Combo Study
June 26, 2019
- Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel
October 10, 2018
- Poxel Forms Japan Outpost, Hitches Janssen’s Kaneko as Country Chief
September 14, 2018
- Poxel Eyeing Japan as 1st Market for Its Lead Diabetes Candidate: CEO
February 6, 2018
- Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med
December 28, 2017
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
BUSINESS
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Japan OTC Market Falls 2.4% in April amid Weaker Inbound Demand: Intage
May 28, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…